Post by Alexion Pharmaceuticals, Inc.

Today kicks off the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, where we’ll be presenting our most recent research in light chain (AL) amyloidosis and paroxysmal nocturnal haemoglobinuria (PNH). We look forward to connecting with the haematology community and demonstrating our commitment to advancing care for people living with rare diseases.